PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
Triple-negative breast cancer is a kind of subtype of the breast cancer that hard to be treated due to the mutation help the cancer escape most clinical treatment. Lung cancer also have this kind of problem that some lung cancer mutation make it become ‘undruggable’. With the development of the chimeric antigen receptor T cell (CAR-T) therapy, it gives the new way for treating these two kinds of cancer. This essay will focus on three possible target TEM8/ANTXR1, mesothelin and receptor tyrosine kinase–like orphan receptor 1 (ROR1), of the CAR T cell to illustrate whether the CAR T cell therapy could be the way for threating the TNBC and lung cancer in clinical and the potential toxicities of the CAR T cells to the patients.
Jianshi Zhu
"The possibility of MSLN, ANTXR1, and ROR1 to become the target of CAR T cell therapy for treating TNBC and lung cancer", Proc. SPIE 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022), 126113G (24 March 2023); https://doi.org/10.1117/12.2669662
ACCESS THE FULL ARTICLE
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
Jianshi Zhu, "The possibility of MSLN, ANTXR1, and ROR1 to become the target of CAR T cell therapy for treating TNBC and lung cancer," Proc. SPIE 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022), 126113G (24 March 2023); https://doi.org/10.1117/12.2669662